Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurosurgery.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology. Skandionkliniken, Uppsala, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical and experimental pathology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
Show others and affiliations
2017 (English)In: Acta Neurochirurgica, ISSN 0001-6268, E-ISSN 0942-0940, Vol. 159, no 11, p. 2217-2221Article in journal (Refereed) Published
Abstract [en]

Craniopharyngiomas are histologically benign but locally aggressive tumors in the sellar region that may cause devastating neurological and endocrine deficits. They tend to recur following surgery with high morbidity; hence, postoperative radiotherapy is recommended following sub-total resection. BRAFV600E mutation is the principal oncogenic driver in the papillary variant of craniopharyngiomas. Recently, a dramatic tumor reduction has been reported in a patient with BRAFV600E mutated, multiply recurrent papillary craniopharyngioma using a combination therapy of BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Here, we report on near-radical reduction of a growing residual BRAFV600E craniopharyngioma using the same neoadjuvant therapy.

Place, publisher, year, edition, pages
2017. Vol. 159, no 11, p. 2217-2221
Keyword [en]
BRAFV600E, Craniopharyngioma, RAF-inhibitor
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-333691DOI: 10.1007/s00701-017-3311-0ISI: 000412754600027PubMedID: 28918496OAI: oai:DiVA.org:uu-333691DiVA, id: diva2:1157461
Available from: 2017-11-16 Created: 2017-11-16 Last updated: 2018-01-08Bibliographically approved

Open Access in DiVA

fulltext(969 kB)5 downloads
File information
File name FULLTEXT01.pdfFile size 969 kBChecksum SHA-512
4ca75e92bf51eda894d618245b9020c9483e347b5f0754bf899eda10ad80127249a13b497591b45b567c1f4ea6c43fa693d587ff0c623330db4a97389c15dbf3
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Rostami, ElhamNyström, Petra WittLibard, SylwiaWikström, JohanCasar Borota, OliveraGudjonsson, Olafur
By organisation
NeurosurgeryExperimental and Clinical OncologyClinical and experimental pathologyRadiology
In the same journal
Acta Neurochirurgica
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 5 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 51 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
v. 2.34-SNAPSHOT
|